News 23/09/2022

World Patient Safety Day 2022 – Medication Without Harm: Deenova teams dress in orange

On Sept 17th and any other day of the year, Deenova teams work in hospitals next to pharmacists and nurses to increase patient safety and reduce therapy errors.

The spirit of World Patient Safety Day – MedicationWithoutHarm covered everyone in orange!

ASL di Alessandria

ASST Brianza – Ospedale di Vimercate

ASST di Cremona

ASST di Pavia

ASST Ospedale Papa Giovanni XXIII di Bergamo

AUSL di Piacenza

Azienda Ospedaliera G. Brotzu di Cagliari

Azienda Ospedaliera San Camillo Forlanini di Roma

Fondazione IRCCS Policlinico San Matteo di Pavia

Ospedale Policlinico San Martino di Genova

Policlinico Universitario Agostino Gemelli di Roma

About Deenova:

Since 2004, Deenova is the undisputed leading supplier of mechatronics solutions for closed loop medications and RFID-based medical devices traceability in the healthcare industry. Deenova’s unique, patented and fully integrated solutions ease the healthcare providers’ growing pressures to improve patient safety, reduce therapy errors, minimize waste and controlled substance diversion, contain costs, and diminish the gap between rising patient volume/acuity and scarce medical staff. Deenova guarantees the simplification of all processes related to the management of medications and implantable/disposable medical devices with an expected cost savings range between 15% and 25%. To know more please visit www.deenova.com  or register for the Deenova Days scheduled from November 23rd to 25th.

News 17/09/2022

World Patient Safety Day 2022 – Medication Without Harm: Deenova headquarter lights up in orange

Today Deenova lights up in orange to observe the World Health Organization World Patient Safety Day 2022 dedicated to ‘Medication Without Harm’. The special lighting of the Piacenza headquarter will last till Monday morning, while the attention to patient safety must always continue.

About Deenova:

Since 2004, Deenova is the undisputed leading supplier of mechatronics solutions for closed loop medications and RFID-based medical devices traceability in the healthcare industry. Deenova’s unique, patented and fully integrated solutions ease the healthcare providers’ growing pressures to improve patient safety, reduce therapy errors, minimize waste and controlled substance diversion, contain costs, and diminish the gap between rising patient volume/acuity and scarce medical staff. Deenova guarantees the simplification of all processes related to the management of medications and implantable/disposable medical devices with an expected cost savings range between 15% and 25%. To know more please visit www.deenova.com  or register for the Deenova Days scheduled from November 23rd to 25th.

News 16/09/2022

World Patient Safety Day 2022 – Medication Without Harm: interview with Laurence A Goldberg

In the context of the World Patient Safety Day 2022 on September 17th promoted by World Health Organization dedicated to the Medication Safety, with the slogan ‘Medication Without Harm’, Deenova interviews Laurence A Goldberg FRPharmS, Independent Pharmaceutical Consultant. According to Mr Goldberg “An estimated 237 million medication errors occur in the NHS in England every year1. This number represents the sum of medication errors over all stages of the medication use process.”

Deenova: what are the most frequent Medication Administration Errors (MAEs) and their causes?

LAG: “Most errors occur during drug administration (54%) followed by prescribing (21%) and dispensing (16%). The most common errors were late or early administration of drugs or drug omission. Distractions and interruptions are a regular part of nurses’ working lives. If these occur when nurses are preparing and administering medicines, they can lead to drug errors that compromise patient safety. Poor numeracy and the need for complex calculations have also been highlighted as contributory factors to medication errors in both hospitals and in the community.

The majority of medication errors (72%) have little/no potential for harm and only 2% have potential to cause severe harm.”

Deenova: what are the consequences for patients and for health care organizations?

LAG: “Patients can suffer adverse effects, including irreversible damage, longer stay in hospital and higher personal costs. Organizations can suffer reputational harm, higher costs and risks of litigation. Health care workers (‘second victims’) can suffer psychological trauma and career damage.”

Deenova: is it possible to avoid medication errors?

LAG: “Yes all medication errors are avoidable. Some can be prevented through process and working environment improvement like uninterrupted medicine rounds and clear instructions and procedures. Other mistakes can be resolved thanks to software solutions such as electronic prescribing and drug administration software, electronic patient record and decision support software. Finally automation is the last mile to ensure complete closed loop medication therapies with automated dispensing and unit dose drug distribution.”

Deenova: what is the impact of automation and technology in Medication Safety?

LAG: “The implementation of automation and technology for medication management liberates the time of health care professionals for direct patient care and thereby increase the overall quality of care. For example, in Germany the introduction of UDD showed a saving of 2.61 WTE nurses per 100 beds.”

Deenova: what is the next step to bring completely safe medication practices to a wider audience?

LAG: “The development of international, multidisciplinary community hubs to share experiences and good practices. The involvement of patients is essential to develop the best safe systems. There are several websites where patients can write about their experiences (https://www.patientsafetylearning.org). Patients and relatives are often invited to speak at national and international healthcare conferences on their experiences of being the victims of medication errors that caused severe harm. Patient advisory boards and patient forums are available to advise governments, healthcare providers and also the pharmaceutical industry on safety issues.”

Deenova: how can we promote and spread ‘Medication Without Harm’ culture all over the world despite economic constraints?

LAG: “Patient safety is typically seen as a strategic priority. This sounds important, but it means that, in practice, health and social care decision-makers will weigh (and inevitably trade-off) the importance of patient safety against other priorities, like finances, resources or efficiency. Patient safety is not just another priority: it is part of the purpose of health care. Patient safety should be non-negotiable.

Medication errors, particularly drug administration errors can be reduced considerably by redesigning packaging, eliminating the preparation of doses in clinical areas and simplifying the medicine rounds. This can all be brought about at no overall additional cost to the healthcare provider by utilizing the efficiencies generated by the new practices. One of the major factors in holding up the development of these newer technologies is the pressures that healthcare workers particularly nurses and pharmacists are under at the present time. They are concerned that they do not have the time to embrace the new technologies even though in the long term, benefits will accrue.

When contracts for injectable drugs are awarded, priority should be given to those products that are presented in a RTA format. Purchasing for safety must be implemented and not just discussed.”

Laurence A Goldberg FRPharmS, Independent Pharmaceutical Consultant, UK.

September 2022

Reference

  1. Elliott RA, Camacho E, Jankovic D, et al. Economic analysis of the prevalence and clinical and economic burden of medication error in England. BMJ Qual Saf 11.06.2020, p. 1-10

doi:10.1136/ bmjqs-2019-010206

About Laurence A Goldberg:

Laurence A Goldberg is an independent pharmaceutical consultant working broadly in areas that are designed to reduce medication errors such as IV compounding robots, planning and organizing seminars with a focus on medication error reduction, medical devices and environmental monitoring for hazardous drugs. He was a former Non-executive Director of the National Patient Safety Agency and before establishing his consultancy service, he worked as a hospital pharmacist for over 30 years. He was designated a Fellow of the Royal Pharmaceutical Society of Great Britain in 1989 and has won several awards for his work in pharmacy. He received the UKCPA Lifetime Achievement Award in 2015 and has over 50 scientific papers to his name, many of them as sole author. For more information: [email protected]

About Deenova:

Since 2004, Deenova is the undisputed leading supplier of mechatronics solutions for closed loop medications and RFID-based medical devices traceability in the healthcare industry. Deenova’s unique, patented and fully integrated solutions ease the healthcare providers’ growing pressures to improve patient safety, reduce therapy errors, minimize waste and controlled substance diversion, contain costs, and diminish the gap between rising patient volume/acuity and scarce medical staff. Deenova guarantees the simplification of all processes related to the management of medications and implantable/disposable medical devices with an expected cost savings range between 15% and 25%. To know more please visit www.deenova.com  or register for the Deenova Days scheduled from November 23rd to 25th.

News 30/08/2022

Unit-dose medicines distribution for hospital inpatients

Laurence Goldberg, an independent pharmaceutical consultant, posted an article on the hub by Patient Safety Learning about unit-dose medicines distribution, increasing attention on this topic in the UK.

Read the original article.

In unit-dose dispensing, medication is dispensed in single doses in packages that are ready to administer to the patient. It can be used for medicines administered by any route, but oral, parenteral, and respiratory routes are especially common.

The system provides a fully closed-loop process where the patient, the drug and the healthcare professional are identified by machine readable codes and the drug administration process is linked directly to the electronic prescription and is fully recorded

There are many variations of unit-dose dispensing. As just one example, when doctors write orders for inpatients, these orders are sent to the central pharmacy. Pharmacists verify these orders and technicians place drugs in unit-dose carts. The carts have drawers in which each patient’s medications are placed by pharmacy technicians—one drawer for each patient. The drawers are labelled with the patient’s name, ward, room and bed number. Sections of each cart containing all medication drawers for an entire nursing unit often slide out and can be inserted into wheeled medication carts used by nurses during their medication administration cycles.

Alternatively, electronic medicine storage cabinets can be located on wards and these are attached to medicine carts which are then filled from the cabinets.

Studies often compare unit-dose dispensing to a ward stock system. In a ward stock system, bulk supplies are issued from the pharmacy; the drugs are stored in a medication room on the ward. The correct number of doses must be taken out of the correct medication container for each cycle and taken to the patient for administration. Liquids must be poured by the nurse from the appropriate bottle and each dose carefully measured.

Evidence for effectiveness of the practice

Though the practice of unit-dose dispensing is generally well accepted and has been widely implemented, the evidence for its effectiveness is modest. Most of the published studies reported reductions in medication errors of omission and commission with unit-dose dispensing compared with alternative dispensing systems such as ward stock systems.

Potential for harm

Unit-dosing shifts the effort and distraction of medication processing, with its potential for harm, from the ward to central pharmacy. It increases the amount of time nurses have to do other tasks but increases the volume of work within the pharmacy. Like the nursing units, central pharmacies have their own distractions that are often heightened by the unit-dose dispensing process itself and errors do occur.

Overall, unit-dose appears to have little potential for harm. The results of most of the observational studies seem to indicate that it is safer than other forms of institutional dispensing. However, the definitive study to determine the extent of harm has not yet been conducted.

A major advantage of unit-dose dispensing is that it brings pharmacists into the medication use process at another point to reduce error. Yet about half of the hospitals in a national survey indicated that they bypass pharmacy involvement by using floor stock, borrowing patients’ medications and hiding medication supplies.

Unit dose drug distribution is being introduced across Europe. In Germany, a recent study showed a saving of 2.61 WTE nurses per 100 beds. There is now growing interest in UK hospitals and pilot sites to develop the system are being established.

News 26/07/2022

Deenova continues to set records in its market growth in France, with 4 new contracts awarded by leading French hospitals

Milan-(BUSINESS WIRE) – Boosting its unstoppable rise in the French market, Deenova announces four new contract awards, for its pioneering and unrivaled D3 series. Three AIDE Pick and two AIDE Cut robots, Deenova’s D3 latest innovative solutions, has been awarded by the Center Hospitalier in Bagnères de Bigorre by winning the competitive UniHA tender. Simultaneously Deenova reports new RESAH contracts for its long established and market leading ACCED robot at University Hospital of Saint-Ètienne and at Center Hospitalier intercommunal de Poissy – Saint-Germain-en-Laye. Finally, Center Hospitalier de Tourcoing, existing Deenova Acced and ASTUS customer, confirms its trust in Deenova D3 solutions with 20 additional ASTUS secured cabinets, through the UniHA tendering.

Loïc Bessin, Managing Director of Deenova France, stated: “With these new contracts, we are now exceeding the bar of 100 Hospital Pharmacy automation solutions in France spread over more than 40 healthcare institutions, which makes Deenova by far the number 1 company in France, with our solutions referenced both at UniHA and RESAH.”

Christophe Jaffuel, Chief Commercial Officer of Deenova, added: “Those recent tender awards are extremely significant for us, not only they confirm our dominant market share in France, with a third year of very strong consecutive growth, but also the early acceptance of our recently launched modular AIDE product line, as well as the solidity of our partnerships with RESAH and UniHA. A positive trend, that we expect to continue in future.”

The Center Hospitalier of Bagnères de Bigorre is a HAS certified facility in the Pyrenees area, offering different services such as functional rehabilitation, general medicine, geriatric SSR, LTC, radiology and therapeutic education, as well as a nursing home.

The University Hospital of Saint-Ètienne is located in the heart of the Auvergne-Rhône-Alpes region. Its activities are organized around 16 poles and 68 services, with 1920 beds distributed over the 3 main sites. The 8,350 professionals care annually for over 170,000 patients in hospitalization and sessions and more than 500,000 in consultations.

The Center hospitalier intercommunal de Poissy – Saint-Germain-en-Laye is a member of the Groupement hospitalier de territoire des Yvelines Nord and is a public institution of reference in care, teaching, and research. It has specialized activity poles with quality of care and safety certified by HAS.

Centre Hospitalier de Tourcoing is a regional hospital with 780 beds, located in the northeast of the The European Metropolis of Lille and a group member of the GHT Lille Métropole Flandre Intérieure. It serves an area of 230 municipalities, with a population of 1.5 million inhabitants, and more than 2000 professionals working together to provide patient care.

Since 2004, Deenova is the undisputed leading supplier of mechatronics solutions for closed loop medications and RFID-based medical devices traceability in the healthcare industry.

Deenova’s unique, patented and fully integrated solutions ease the healthcare providers’ growing pressures to improve patient safety, reduce therapy errors, minimize waste and controlled substance diversion, contain costs, and diminish the gap between rising patient volume/acuity and scarce medical staff.

Deenova guarantees the simplification of all processes related to the management of medications and implantable/disposable medical devices with an expected cost savings range between 15% and 25%.

News 11/07/2022

Deenova Continues Its Innovation Streak With the Unveiling of the Next Generation of ALL-IN-1, its Cutting-Edge All Medication Forms Unit Dose Repackaging Robot

MILAN–(BUSINESS WIRE)–Following its previous announcements in March 2022, for the release of three new innovative additions to its award winning D3 product line of mechatronic solutions, Deenova further consolidates its technological leadership in the field of pharmacy automation, and announced today the unveiling of the second generation of its ALL-IN-1 robot, able to automatically repack in unit dose, all medication forms: oral solids and liquids such as ampoules, syringes, vials and all types of patches sachet and suppositories.

The ultimate generation of this innovative fully automated repackaging robot has been designed to ensure the efficiency and unmatched fluency of its predecessor, while improving versatility and reliability with optimized movements of the robotic arm.

With the operator in mind, and for an unrivaled customer experience, particular attention has been put in the functional aspects of the technology such as improving the vision system with new AI functionalities, lowering the overall noise level, improving the ergonomics and developing a smooth and intuitive user interface, perfectly in line with Deenova’s vision of “sensitive robotics”: a technology in contact with the human side in a reliable support relationship anytime, anywhere.

Fulvio Rudello, Chief Operation Officer at Deenova, declared: “I am very excited to see that our new ALL-IN-1 robot has successfully passed all the factory validation tests, and is now fully operational in Deenova’s central unit dose laboratory near Piacenza, serving 22 hospitals sites in Italy, with more than 6 millions unit doses produced per year. This is the first step of a wider upgrading process of our facility and will be followed by the gradual replacement of existing equipment starting with implementation during the first quarter of 2023, of the new D3 AIDE CutDeenova‘s latest modular mechatronic solutions for the repackaging of oral solid medications in unit doses.”

“Our 100% customer retention rate in Italy, after more that 15 years of operations” explained Christophe Jaffuel, Chief Commercial Officer at Deenova “motivates us to relentlessly define new standards of performance and customer experience. Having this new ALL-IN-1 robot, fully operating in our facilities is a great premise for our upcoming breakthrough installations in UK and Germany”.

Since 2004, Deenova is the undisputed leading supplier of mechatronics solutions for closed loop medications and RFID-based medical devices traceability in the healthcare industry. Deenova’s unique, patented and fully integrated solutions ease the healthcare providers’ growing pressures to improve patient safety, reduce therapy errors, minimize waste and controlled substance diversion, contain costs, and diminish the gap between rising patient volume/acuity and scarce medical staff. Deenova guarantees the simplification of all processes related to the management of medications and implantable/disposable medical devices with an expected cost savings range between 15% and 25%.

News 20/06/2022

At the Nîmes University Hospital, pill dispensers are in the hands of Deenova, a robot

Reducing errors, limiting waste and optimising the working time of health care staff. Le Réveil du Midi (a French regional newspaper) reports on the benefits coming from the arrival of Deenova robots at the Nîmes University Hospital: they prepare pillboxes automatically.

Read the original article in French.

Last Friday, the director of the Nîmes University Hospital, Nicolas Best, presented a small innovation that was installed a fortnight ago in the hospital’s internal pharmacy… From now on, a 100% automated process handles the pillboxes used to administer treatment to patients.

It is no longer the small hands of the pharmacist but those of the robot, which will henceforth fill the pillboxes of the Nîmes University Hospital. The principle is simple: using its arm, Deenova (the robot) prepares the boxes, extracts the tablet from its packaging and places it in the pillbox. Once completed, all that remains for the nurse or pharmacist to do is to retrieve the ready-to-use pillbox.

piluliers_chudenimes_pharmacieinterne_deenova_chaineautomatisee_reveildumidi_1.jpg

A pharmacist collects the ready-to-use pill boxes. © G. Ohan-Tchelebian

The entire chain is robotized and no longer requires human intervention, except in the event of a control. Still at the start-up stage, checks are carried out regularly.

5 robots for a total of 1.3 million euros

60m2 will have been enough to install these 5 robots. For the moment, the capacity achieved by the robots ensures the filling of pillboxes for 400 beds. It is planned to achieve 1600 beds by September 2022.

When asked what will happen to the healthcare staff initially responsible for these repetitive tasks, the pharmacist explains that their replacement by the robot is beneficial: “It is not possible to hire untrained staff even to fill pillboxes, the robots will free about twenty pharmacists from a not entirely exciting and high-risk job that can be redeployed on care services” explains Jean-Marie Kinowski, pharmacist at the Nîmes University Hospital.

deenova_piluliers_chudenimes_robots_chaineautomatisee_reveildumidi_1.jpg

Jean-Marie Kinowski, pharmacist at the Nîmes University Hospital, presents Deenova, a 100% robotic line for preparing pillboxes © G. Ohan-Tchelebian

Another advantage is the time saved. With Deenova, 50 pillboxes are prepared per hour, per robot. In total, 250 pillboxes are prepared in one hour by the 5 robots. Needless to say, in terms of efficiency, this is far from being possible on human scale and the increase in production volume in a reduced time is considerable.

A secure medication circuit

Preparation is done on a day-to-day basis, which avoids an administration error if a patient changes department. For example, if a patient is transferred during the day, the next day’s pillbox is prepared after the patient’s visit or after the evening’s counter-visit once he or she is settled in the new room. So, no weekly pillboxes.

The big advance that everyone agrees on concerns the unit doses. Sometimes the doses are not written on the tablet but on the packaging, so once out, it is difficult to remember which tablet it is if you forget “the white capsules all look the same”. The robot does not forget. The risk of error is eliminated, and no more wastage. The right medicine, to the right patient, at the right time.

News 20/06/2022

Deenova´s France Remarkable and Continued Success Extends to French overseas departments: winning Mayotte, GHPSO and I.N.I. Awards

MILAN–(BUSINESS WIRE)–Deenova today disclosed that it expanded its market dominance in France with another net new UniHA competitive award for its D3 ACCED mechatronic solution at Centre Hospitalier de Mayotte in French overseas departments. Additionally, Deenova announced a new competitive tender win at GHPSO Creil & Senlis also for its market leading D3 ACCED mechatronic robot through its partnership with another premier hospital group, RESAH. Separately, Deenova is pleased to simultaneously report additional add-on sales of its unique ASTUS cabinets and D3 ACCED to existing Deenova customer Institute Nationale des Invalides in Paris, also through its UniHA partnership.

Loïc Bessin, Managing Director of Deenova in France stated: “Bringing together net new business tender wins at Centre Hospitalier de Mayotte and GHPSO Creil & Senlis for our D3 ACCED mechatronic solutions, while at the same time earning the trust of additional sales to previous Deenova ASTUS customers such as Institute Nationale des Invalides is steady evidence of Deenova France unparalleled success in our industry, undoubtedly showing the market a high level of reliable customer satisfaction in France.”

Christophe JaffuelDeenova Chief Commercial Officer, added: “A new milestone for Deenova is reached: expansion beyond the European continent, a great ongoing incentive for our sales teams. I am very appreciative for the important and yearly contribution that both UniHA and RESAH ongoing multi-year tender awards means to Deenova in France and now beyond, renewing its past commitment to Deenova market-leading Unit-Dose solutions. I look forward to continuing the outstanding cooperation with UniHA and RESAH in the near future.”

Centre Hospitalier de Mayotte, a public health establishment with 543 beds, is the only hospital in the overseas Department of Mayotte. It is located in the northern part of the Mozambique Channel in the Indian Ocean off the coast of Southeastern Africa. It provides both hospital care and out-patient care with 4 localized care and childbirth centers (North, Centre, South and Petite-Terre) of intermediate level, providing general consultations and a 24-hour medical service and 7 days a week.

GHPSO Creil & Senlis, located just 30 minutes from Paris CDG airport, offers a complete emergency service: Adult, Paediatric and Gyneco-obstetrics with 584 full hospital beds, 46 day hospitalization places, 21 haemodialysis stations, and on the other hand an offer in Follow-up and Rehabilitation Care (SSR) with 32 beds, in accommodation with 73 Long-Term Care Unit beds (USLD), 90 beds in an Accommodation Establishment for Dependent Elderly Persons (EHPAD) and 12 places in Alzheimer’s day centre, i.e. a total of 858 beds. The SMUR unit intervenes at the request of the SAMU de l’Oise.

Institute Nationale des Invalides is placed under the supervision of the French Government Ministry of Defense and Veterans Affairs. It is responsible for welcoming veterans who are victims of severe handicaps linked to war wounds. It includes three complementary centers: the Pensioners’ Center, the Post-Traumatic Rehabilitation Center and the Center for Studies and Research on Equipment for the Handicapped. A total of 91 single rooms are fully equipped for patients in the Paris metropolitan area.

UniHA, the Union of Hospitals for Purchasing, is a cooperative of French public hospital buyers created in 2005 by the hospital staff themselves (32 CHU and 20 CH). As of 2022, 1.065 hospitals have joined the UniHA cooperative, with 115 GHT having conducted € 5.6 billion in group purchases in 2021. UniHA is one of the main European buyers in the field of health and one of the first national buyers, all sectors of activity combined. The essential challenge: to provide citizens with the best treatments available, to provide high-quality hospital services, and to preserve equal access to care.

RESAH is a public interest group (GIP) whose objective is to support the pooling and professionalisation of purchases from the health sector, public and private non-profit. It was created in 2007 to support the pooling of hospital purchases for the Ile-de-France region, in collaboration with Achat Hopital.

Deenova is the undisputed leading supplier of combined mechatronics (robotic and automation) solutions for closed loop medications and RFID-based medical devices traceability in the healthcare industry, anytime and anywhere. Deenova’s unique, patented, and fully integrated solutions have and will greatly contribute to ease healthcare providers’ growing pressures to: simultaneously improve patient safety, reduce therapy errors, minimise waste and controlled substance diversion, contain costs, and diminish the gap between rising patient volume/acuity and scarce medical staff. Deenova guarantees the simplification of all processes related to the management of medications and implantable/disposable medical devices with an expected cost savings range between 15% and 25%.

News 31/05/2022

Deenova Wins New Italian Public Tender at IRCCS Policlinico San Matteo in Pavia, Lombardy

MILAN–(BUSINESS WIRE)–Deenova reported today it recently beat its main competitors and was awarded a public tender for IRCCS Policlinico San Matteo named “Open telematic procedure for the acquisition of an integrated information system for the management of drug therapy and the traceability of drugs and medical devices” by decree of the General Manager No. 5/D.G./334 as of March 18, 2022. This new Deenova customer in Italy includes the implementation and services for its many clinicians utilization at the point of care of 100 prescription trolleys, 100 administration trolleys, 100 barcode readers, 200 portable PCs, and 100 label printers.

Fulvio Rudello, Chief Operating Officer at Deenova stated: “This IRCCS Policlinico San Matteo is another testament of Deenova´s Closed-Loop solutions undisputed European leadership in the healthcare industry. It cements the economic balance of continuing to add net new customers in Europe while at the same time proudly show a 100% retention rate of our existing customers, metrics that have no parallel in the health care sector.”

The IRCCS Policlinico San Matteo in Pavia has over 1.000 accredited beds serving 700.000 inhabitants in Lombardy, divided into about 60 operating units with teaching, health care assistance, and research activities. Among its units there are many areas of excellence, with approximately about 3.300 employees including doctors, nurses, technicians and administrators, offering 36.500 hospitalizations (13,7% of which to patients outside the region), 99.000 emergency room visits and 2.1 million outpatient visits.

Deenova is the undisputed leading supplier of combined mechatronics (robotic and automation) solutions for closed loop medications and RFID-based medical devices traceability in the healthcare industry, anytime and anywhere. Deenova’s unique, patented, and fully integrated solutions have and will greatly contribute to ease healthcare providers’ growing pressures to: simultaneously improve patient safety, reduce therapy errors, minimise waste and controlled substance diversion, contain costs, and diminish the gap between rising patient volume/acuity and scarce medical staff. Deenova guarantees the simplification of all processes related to the management of medications and implantable/disposable medical devices with an expected cost savings range between 15% and 25%.

News 17/05/2022

Deenova Keeps Up its Competitive Streak in France with 2 New Tender Awards at Hazebrouck and Mantes-La-Jolie

MILAN–(BUSINESS WIRE)– Deenova today announced that it continued its last 2 years market dominance in France with another net new RESAH competitive award for its D3 ACCED mechatronic solutions at Centre Hospitalier Hazebrouck near Dunkerque. Separately, Deenova is pleased to simultaneously announce add-on sales of 4 ASTUS cabinets to existing Deenova customer Centre Hospitalier François Quesnay de Mantes-La-Jolie.

Loïc Bessin, Managing Director of Deenova in France stated: “Combining net new business awards at premier hospital groups like RESAH with Centre Hospitalier Hazebrouck, while at the same time earning the trust of additional add-on sales by previous Deenova customers such as Centre Hospitalier François Quesnay de Mantes-La-Jolie is self-evident proof of Deenova France maturity, showing a high level of continued satisfaction with our automation solutions amongst our existing customer base in France.”

Christophe JaffuelDeenova Chief Commercial Officer, added: “I am extremely pleased to continue to witness since 2019 the important and yearly contribution that RESAH ongoing awards means to Deenova in France, renewing its past commitment to Deenova well established mechatronic Unit-Dose solutions like D3 ACCED. I look forward to continuing the market leading cooperation with RESAH in the future.”

Centre Hospitalier Hazebrouck is a public health establishment located in the Lille Métropole healthcare area, and certified by the High Authority for Health in 2019. It assumes the functions of a local hospital for a population of approximately 124,000 inhabitants, with a capacity of 94 hospital beds, centered on medicine, surgery and gynecology-obstetrics, an Emergency Reception Service and a Home Hospitalization service. It also has an accommodation structure for the elderly (EHPAD) with 136 beds, a CSAPA (Centre for Care, Support and Prevention in Addictology) and 20 Aftercare and Rehabilitation beds. Patients benefit from consultations and expert advice as well as a high-quality technical platform with a medical imaging, 4 operating theaters, 3 birthing rooms, a pharmacy and sterilization units with 470 medical and non-medical staff.

Centre Hospitalier François Quesnay de Mantes-La-Jolie is a public health establishment opened in October 1997, bringing together all short-stay services (medicine, surgery, obstetrics), Aftercare and Rehabilitation (SSR), with 612-bed hospital in the Paris metropolitan area, and with a budget of 125 million euros and 175 doctors.

Deenova is the undisputed leading supplier of combined mechatronics (robotic and automation) solutions for closed loop medications and RFID-based medical devices traceability in the healthcare industry, anytime and anywhere. Deenova’s unique, patented, and fully integrated solutions have and will greatly contribute to ease healthcare providers’ growing pressures to: simultaneously improve patient safety, reduce therapy errors, minimise waste and controlled substance diversion, contain costs, and diminish the gap between rising patient volume/acuity and scarce medical staff. Deenova guarantees the simplification of all processes related to the management of medications and implantable/disposable medical devices with an expected cost savings range between 15% and 25%.